TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 28.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,257 shares of the company's stock after selling 4,048 shares during the quarter. J.W. Cole Advisors Inc.'s holdings in TransMedics Group were worth $1,610,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. State of Alaska Department of Revenue purchased a new stake in shares of TransMedics Group during the third quarter valued at $2,560,000. Louisiana State Employees Retirement System purchased a new stake in TransMedics Group during the 3rd quarter valued at about $2,528,000. Guidance Capital Inc. purchased a new position in shares of TransMedics Group in the third quarter worth about $370,000. Precision Wealth Strategies LLC acquired a new stake in shares of TransMedics Group during the third quarter worth about $236,000. Finally, Evernest Financial Advisors LLC purchased a new stake in TransMedics Group in the third quarter valued at approximately $259,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TMDX has been the subject of a number of recent research reports. Piper Sandler reissued an "overweight" rating and set a $180.00 price target on shares of TransMedics Group in a research report on Tuesday. Oppenheimer reduced their target price on shares of TransMedics Group from $200.00 to $125.00 and set an "outperform" rating for the company in a report on Tuesday. Needham & Company LLC lowered their price target on shares of TransMedics Group from $208.00 to $109.00 and set a "buy" rating on the stock in a report on Tuesday. JPMorgan Chase & Co. cut their price target on TransMedics Group from $173.00 to $116.00 and set an "overweight" rating on the stock in a research report on Tuesday. Finally, Robert W. Baird decreased their price objective on TransMedics Group from $200.00 to $150.00 and set an "outperform" rating for the company in a report on Tuesday. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $144.80.

TransMedics Group Price Performance

TMDX traded down $37.74 during trading on Tuesday, hitting $88.50. The company's stock had a trading volume of 11,660,088 shares, compared to its average volume of 914,126. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of 94.15 and a beta of 1.99. The business's fifty day simple moving average is $146.02 and its 200 day simple moving average is $140.16. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.16). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group's revenue was up 63.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.12) EPS. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1.22 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total value of $1,144,623.75. Following the sale, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company's stock, valued at approximately $8,180,642.53. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Tamer I. Khayal sold 2,958 shares of the business's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,205 shares of company stock valued at $9,981,907 over the last 90 days. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.